BioMedNewsBreaks – Healthy Extracts Inc.’s (HYEX) Specialized Team Poised to Expand Doctor-to-Doctor, Consumer Sales

Healthy Extracts (OTCQB: HYEX) recently announced the addition of Dr. Joel Kahn, MD, to its medical board. Dr. Kahn, a world-renowned, triple board-certified cardiology specialist with 30 years of experience, has used BergametNA Citrus Bergamot SuperFruit(TM) on thousands of patients and approves the product’s cardiovascular health benefits. He has also personally conducted clinical studies that confirm the effectiveness of the superfruit, the main ingredient in BergametNA’s product line. HYEX CEO Duke Pitts noted that the company was delighted to welcome Dr. Kahn to its medical board. A recent article discussing this indicates that Pitts considers the addition of Dr. Kahn to the company’s already talented team of specialized doctors as instrumental in expanding doctor-to-doctor and consumer sales.

To view the full article, visit https://ibn.fm/zbORz

About Healthy Extracts Inc.

“Live Life Young Again”

Healthy Extracts serves as a platform for developing and acquiring complementary companies that feature science-forward, clinically proven, plant-based and proprietary products in select high-margin and high-growth categories within the multibillion-dollar nutraceuticals market – the first two multimillion-dollar examples of which have already been launched.

Company subsidiaries BergametNA(TM) and Ultimate Brain Nutrients(TM) (“UBN”) are providers of nutraceutical natural heart and brain health supplements, including the only heart health supplement containing Citrus Bergamot SuperFruit(TM), the highest quality and concentration of polyphenols and flavonoids available anywhere in the world and exclusive to BergametNA in North America and backed by 17 clinical studies. UBN’s KETONOMICS(R) proprietary formulations improve brain health, including memory, cognition, focus and neuro-energy, and have multiple intellectual property license opportunities for monetizing the company’s portfolio. UBN has six unique formulation patents — two issued and four pending.

For more information, visit: www.HealthyExtractsinc.com, www.BergametNA.com or www.Fuel4Thought.com.  

NOTE TO INVESTORS: The latest news and updates relating to HYEX are available in the company’s newsroom at https://ibn.fm/HYEX

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

 

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Submits IND Amendment for Planned Phase 2a Trial of TTX-MC138 in Colorectal Cancer

TransCode Therapeutics (NASDAQ: RNAZ) announced the submission of an Investigational New Drug ("IND") application amendment…

7 hours ago

BioMedNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports New Cellular Data Demonstrating Coordinated Intracellular Zinc Increase and Iron Reduction With Telomir-Zn

Telomir Pharmaceuticals (NASDAQ: TELO) announced new cellular study results showing that Telomir-1, administered as Telomir-Zn,…

7 hours ago

BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Engages DUCK FLATS Pharma for IND Readiness and Regulatory Execution

Oragenics (NYSE American: OGEN) announced that it has engaged DUCK FLATS Pharma as its U.S.…

2 days ago

BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Participates in SCOPE Summit 2026 Ahead of Phase 2a Concussion Trial

Oragenics (NYSE American: OGEN), a clinical-stage biotechnology company developing intranasal therapeutics for neurological disorders, announced…

3 days ago

BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Mission Matters Podcast Interview With President Anil Diwan

NanoViricides, Inc. (NYSE American: NNVC) announced that President Dr. Anil R. Diwan was interviewed on…

3 days ago

BioMedNewsBreaks — VolitionRx (NYSE American: VNRX) Prepares Reimbursement Submission for Nu.Q Cancer Assays in France

VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced that it is preparing a reimbursement submission for its Nu.Q®…

6 days ago